1407. Fecal Bacteriotherapy in Community Hospital: Satisfaction and Effectiveness from the Patient Perspective
Session: Poster Abstract Session: Clostridium difficile
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • IDSA PDF revised 1407.pdf (539.9 kB)
  • Background: While ongoing studies confirm the effectiveness of fecal bacteriotherapy (FB) as a treatment option for recurrent Clostridium Difficile Infections (CDI), limited data has been collected regarding the patient’s perception of the procedure and whether perceived benefits of FB outweigh the repugnance of the process.

    Methods: Study used retrospective quasi-experimental design examining patients’ impressions of the short-term (2-10 days post procedure) and long-term (over 3 months) effectiveness of FB along with patient satisfaction with FB.   Consecutive sampling methods of 34 patients who underwent FB from 2009-2012 resulted in 28 eligible subjects based on criteria of being 3 months post procedure and cognitively able to complete the survey.   Survey developed in collaboration with GI and ID specialists and used 0-10 rating scale for questions regarding pain (0=no pain, 10 worst pain ever), nausea (0=no nausea, 10= severe nausea) and patient satisfaction (0=least satisfied/least likely, 10=most satisfied/very likely), dichotomous (Yes/No) questions for long-term results, and checklist questions for stool frequency.   28 surveys sent with 20 returned (n=20, 71%).  

    Results:  Average age of respondent was 67 years (+/-13.98) and female to male ratio 15:5.  Short-term outcomes: Average abdominal pain scores dropped from 6.5 to 1.7; nausea average scores dropped from 4 to 1.2; at 10 days post procedure, 100% respondents had <4 stools per day.  Long-term outcomes: At >3 months post procedure, 17 of 20 (85%) had no further episodes of diarrhea requiring physician or hospital visit; 17 of 20 (85%) had no further nausea requiring physician or hospital visit; 18 of 20 (90%) had no further abdominal cramping requiring physician or hospital visit.  Patient satisfaction: Average satisfaction score with overall results of procedure was 9.6 (+/-1.10) average satisfaction score in regards to cost associated with procedure was 9.6 (+/-1.27); average satisfaction score regarding facility was 9.9 (+/-0.31); and how likely to recommend procedure to family/friend was 9.9 (+/-0.45). 

    Conclusion: Results suggest high patient satisfaction with FB as treatment for recurrent CDI despite the procedure’s anticipated repugnance.  Patients also reported significant improvement in short-term and long-term symptoms of pain, nausea and diarrhea.

    Ravi Kamepalli, MD, Infectious Diseases and Wound Care, Regional Infectious Disease-Infusion Center, Lima, OH and Laurie Schnipke, RN, BSN, Infectious Diseases and Wound Care, Regional Infectious Diseases-Infusion Center, Inc., Lima, OH

    Disclosures:

    R. Kamepalli, None

    L. Schnipke, None

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.